12:00 AM
 | 
Mar 12, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/9 cls
Anesiva (ANSV) Lazard Megan Murphy New Buy 1% $7.56
Murphy set a $10 target. She believes 4975, a non-narcotic injectable capsaicin anesthetic, will enter Phase III trials this year and is an asset with low clinical risk and significant market potential. She expects a 2008 partnership for moderate and severe osteoarthritis.
Aspreva (TSX:ASV; ASPV) Stanford Group Hanzhong Li New Buy -5% $20.99
Li set a $28 target. He believes ASV has a favorable risk/reward profile as CellCept's off-label autoimmune sales continue to grow ahead of Phase III data for lupus nephritis, which are expected in 2Q07. ASV has rights from Roche (SWX:ROG) to develop and commercialize CellCept in all autoimmune indications. The product is approved for organ transplant rejection.
CollaGenex (CGPI) Rodman Ren Benjamin Price target Market outperform -4% $13.30
Benjamin raised his target to $19 from $16 after CGPI announced a 4Q06 loss per share of $0.28 vs. his estimate of a loss of $0.43, due in part to higher than expected revenues.
CV Therapeutics (CVTX) Cantor Fitzgerald George Zavoico Price target

Read the full 1097 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >